▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / PGEN

PGEN — PRECIGEN, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1356090 ·
Last close
$4.45
Market Cap
$1.59B
52W High
$4.87
52W Low
$3.04
ADV30
4,566,913
Next earnings
2026-08-11
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 23,252,000 20,693,000 -5,994,000 -7,929,000 138,627,000 7,480,000 118,392,000
Dec 2025 4,565,000 2,969,000 -21,666,000 -23,503,000 155,505,000 30,234,000 134,594,000
Sep 2025 2,922,000 1,887,000 -34,481,000 -146,344,000 171,264,000 14,322,000 129,396,000
Jun 2025 856,000 -236,000 -27,857,000 -26,642,000 101,896,000 13,760,000 138,675,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-115,333,000
Investing CF
$25,889,000
Financing CF
$90,836,000
CapEx
$-1,631,000
Dividends Paid
—
Buybacks
$-1,841,000
EPS Diluted TTM
$-1.35
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,349,277,000
Inventory
$14,725,000
Receivables
$26,705,000
ST Investments
$48,766,000
EBIT TTM
$-197,641,000
Pretax Income TTM
$-204,415,000
Interest Exp TTM
$6,774,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$31,595,000
EBITDA
$-86,329,000
Free Cash Flow
$-90,111,504
Enterprise Value
$1,628,477,824
Total Cash
$56,246,000
Total Debt
$98,250,000
Shares Out
356,510,980
Trailing EPS
$-1.21
Book Value
$0.06
ROE
-1145.4%
ROA
-42.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,684,000 -106,600,000 -250,642,000 155,505,000 134,594,000 — -87,831,000
Dec 2024 3,925,000 -94,705,000 -126,235,000 145,266,000 106,753,000 — -68,173,000
Dec 2023 6,225,000 -88,923,000 -95,904,000 151,043,000 32,545,000 — -66,930,000
Dec 2022 26,909,000 -74,606,000 28,317,000 215,977,000 89,718,000 — -65,045,000

TTM Snapshot

Revenues TTM
$3,333,000
NetIncome TTM
$13,842,000
OpCashFlow TTM
$0
Assets (Latest)
$145,266,000
Forward EPS
$-0.22

Max Pain — expiry 2026-06-18

max pain strike: $4.00 · spot: $4.80 · call oi: 4,757 · put oi: 2,808
Expected Move to 2026-06-18: ±$0.64 (13.33%) — implied range $4.16 – $5.44 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GENB Generate Biomedicines, Inc. $1.59B $12.38 —
ABCL AbCellera Biologics Inc. $1.60B $5.24 —
TYRA Tyra Biosciences, Inc. $1.61B $26.99 —
PVLA PALVELLA THERAPEUTICS, INC. $1.56B $108.81 —
SRPT Sarepta Therapeutics, Inc. $1.62B $15.31 —

News headlines (Yahoo Finance, 1h cache)

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
2026-06-15 10:40 · Yahoo
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate
2026-06-14 16:11 · Yahoo
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
2026-06-12 20:05 · Yahoo
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
2026-06-11 12:00 · Yahoo
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
2026-06-01 16:00 · Yahoo
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
2026-05-30 18:30 · Yahoo
Spotlight On 3 Growth Companies With Strong Insider Stakes
2026-05-26 17:36 · Yahoo
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-26 12:05 · Yahoo
Precigen (PGEN): The Best Penny Stock to Buy for Long Term
2026-05-22 18:41 · Yahoo
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-16 12:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →